|
|
Mastoparan 7 |
|
Vaxjo ID |
175 |
|
Vaccine Adjuvant Name |
Mastoparan 7 |
|
Adjuvant VO ID |
VO_0005380
|
|
Description |
nanoparticle peptide adjuvant with TLR9 ligand CpG that induces Th2 response |
|
Stage of Development |
Research |
|
Location Licensed |
US (Duke University) |
|
Host Species for Testing |
3 |
|
Second Host Species for Testing |
6 |
|
Components |
M7 peptide, CpG |
|
Storage |
store lyophilized peptides at -20; store reconstituted peptide at -80 |
|
Preparation |
M7 peptide in PBS (1mg/mL) combined with Nitrogen/Phosphate ratios with CpG ODN 1826 and sonicated in a water bath at 100% amplitude |
|
Function |
activation of mast cells,epithelial cells, macrophages and dendritic cells |
| References |
(Staats, 2024): Vaccine Adjuvant Compendium - VAC [https://vac.niaid.nih.gov/view?id=53]
St et al., 2020: St John AL, Choi HW, Walker QD, Blough B, Kuhn CM, Abraham SN, Staats HF. Novel mucosal adjuvant, mastoparan-7, improves cocaine vaccine efficacy. NPJ vaccines. 2020; 5(1); 12. [PubMed: 32047657].
|
|
